Will the Dong Wha Pharm’s ‘Zabolante’ lead the antibiotic market?
The Dong Wha Pharm’s quinolones- type antibiotic, ‘Zabolante (zabofloxacin)’, which acquired a new drug approval from the Ministry of Food and Drug Safety on 20 March, has attracted attention of the industry. Although the size of the market has increased 6% up annually at approximately KRW 120 bi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
